Market Research Logo

Therapeutics for 'Silent' Cancers

Therapeutics for 'Silent' Cancers

The global market for “silent” cancers was valued at $8.5 billion in 2013 and $9 billion in 2014. This market is expected to reach almost $13.6 billion by 2019, with a compound annual growth rate (CAGR) of 8.5% from 2014 to 2019.

This report provides:

An overview of the global markets and technologies for the therapeutics for "silent" cancers.

Analyses of global market trends, with data from 2013, 2014, and projections of CAGRs through 2019.

Descriptions of cancers, with incidence and prevalence data for all major national markets.

Assessments of currently available therapies.

Evaluation of new agents now in clinical development, with likely launch timetables and estimates of potential clinical value.

Profiles of major players in the "silent" cancer therapeutics industry.


SCOPE OF REPORT

The report discusses eight cancers described as “silent and deadly” because they are often undiagnosed until the diseases is advanced and difficult to treat. These cancers are brain, cervix, esophagus, mouth and larynx, ovary, pancreas, kidney, and lastly, liver. For each cancer, the cause, clinical course, diagnosis and treatment are described. Current drug therapy is outlined and new research activities are listed. The market is summarized and quantified for each cancer, with estimates of recent (2013) and current (2014) values for each cancer, and five-year projection to 2019. Geographically, the global market is given, with country analyses for the U.S., Japan, and five major Western European markets: Germany, France, Italy, Spain and the United Kingdom.

CHAPTER 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
MARKET ANALYSES AND FORECASTS
METHODOLOGY
INTENDED AUDIENCE
INFORMATION SOURCES
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 SUMMARY
SUMMARY TABLE GLOBAL MARKET FOR "SILENT" CANCERS, THROUGH 2019 ($ MILLIONS)
SUMMARY FIGURE GLOBAL MARKET SHARE FOR (%)
CHAPTER 3 OVERVIEW
CANCER: A GLOBAL PERSPECTIVE
GROWING PROBLEM
MARKET DYNAMICS
SOME LEADING ANTICANCER DRUGS
DRUG CATEGORIES
ASYMPTOMATIC CANCER
TELLTALE GENES
TUMOR MARKERS
CHAPTER 4 BRAIN CANCER
CAUSE, FREQUENCY AND COURSE
DIAGNOSIS
IMAGING TESTS
MRI
CT Scan
PET Scan
Cerebral Arteriogram
Lumbar Puncture or Spinal Tap
Myelogram
Tissue Sampling/Biopsy/Surgical Removal of a Tumor
PROGNOSIS
TREATMENT
RADIATION THERAPY AND NEUROTOXICITY
CHEMOTHERAPY
NEW DEVELOPMENTS IN RESEARCH
TABLE 1 COMPOUNDS IN CLINICAL DEVELOPMENT FOR BRAIN CANCER
RECENT RESEARCH REPORTS
MARKET
TABLE 2 GLOBAL AND U.S. BRAIN CANCER MARKET, THROUGH 2019 ($ MILLIONS)
TABLE 3 BRAIN CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
TABLE 4 BRAIN CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)
CHAPTER 5 CANCER OF THE MOUTH AND LARYNX
CAUSE, FREQUENCY AND COURSE
DIAGNOSIS
TREATMENT
LARYNGEAL CANCER
CAUSE, FREQUENCY AND COURSE
DIAGNOSIS
TREATMENT
NEW RESEARCH DEVELOPMENTS
TABLE 5 COMPOUNDS IN CLINICAL DEVELOPMENT FOR HEAD AND NECK
CANCER
LYMPHOSEEK
REOLYSIN
MULTIKINE
MARKET
TABLE 6 GLOBAL AND U.S. MOUTH AND LARYNX CANCER MARKET, THROUGH 2019 ($ MILLIONS)
TABLE 7 MOUTH AND LARYNX CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
TABLE 8 CANCER OF MOUTH AND LARYNX FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)
CHAPTER 6 CANCER OF THE ESOPHAGUS
CAUSE, FREQUENCY AND COURSE
DIAGNOSIS
TREATMENT
NEW RESEARCH DEVELOPMENTS
GENETICS
SCREENING AND PREVENTION
SURGERY
CHEMOTHERAPY
TARGETED DRUGS
TABLE 9 COMPOUNDS IN CLINICAL DEVELOPMENT FOR ESOPHAGEAL
CANCER
MARKET
TABLE 10 GLOBAL AND U.S. ESOPHAGEAL CANCER MARKET, THROUGH 2019 ($ MILLIONS)
TABLE 11 ESOPHAGEAL CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
TABLE 12 ESOPHAGEAL CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)
CHAPTER 7 LIVER CANCER
CAUSE, FREQUENCY AND COURSE
DIAGNOSIS
TREATMENT
OTHER PRIMARY LIVER CANCERS
METASTASES
NEW RESEARCH DEVELOPMENTS
VIRUS THERAPY
TABLE 13 LIVER CANCER: NEW DEVELOPMENTS IN RESEARCH
MARKET
TABLE 14 GLOBAL AND U.S. LIVER CANCER MARKET, THROUGH 2019 ($ MILLIONS)
TABLE 15 LIVER CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
TABLE 16 LIVER CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)
CHAPTER 8 RENAL CANCER
CAUSE, FREQUENCY AND COURSE
DIAGNOSIS
TREATMENT
NEW RESEARCH DEVELOPMENTS
GENETICS
NEW APPROACHES TO LOCAL TREATMENT
TARGETED THERAPIES
IMMUNOTHERAPY
VACCINES
BONE MARROW OR STEM CELL TRANSPLANT
TABLE 17 RENAL CANCER: NEW RESEARCH DEVELOPMENTS
MARKET
TABLE 18 GLOBAL AND U.S. RENAL CANCER MARKET, THROUGH 2019 ($ MILLIONS)
TABLE 19 RENAL CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
TABLE 20 RENAL CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)
CHAPTER 9 CANCER OF THE PANCREAS
CAUSE, FREQUENCY AND COURSE
DIAGNOSIS
TREATMENT
NEW RESEARCH DEVELOPMENTS
TABLE 21 PANCREATIC CANCER: NEW RESEARCH DEVELOPMENTS
MARKET
TABLE 22 GLOBAL AND U.S. PANCREATIC CANCER MARKET, THROUGH 2019 ($ MILLIONS)
TABLE 23 PANCREATIC CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
TABLE 24 PANCREATIC CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)
CHAPTER 10 CANCER OF THE CERVIX
CAUSE, FREQUENCY AND COURSE
DIAGNOSIS
TREATMENT
PREVENTION: VACCINES
TREATMENT
Cisplatin
Ifosfamide (Ifex)
Fluorouracil (Adrucil)
Paclitaxel (Taxol)
Topotecan (Hycamtin)
Docetaxel
Gemcitabine
Vaccines: Inactivated, Viral
Human Papillomavirus Vaccine, Quadrivalent (Gardasil)
Human Papillomavirus Vaccine, Bivalent (Cervarix)
Targeted Drug Therapy
NEW RESEARCH DEVELOPMENTS
IXEMPRA
ISA101 VACCINE
VELIPARIB
OLAPARIB
Avastin
TABLE 25 NEW RESEARCH DEVELOPMENTS IN CERVICAL CANCER
MARKET
TABLE 26 GLOBAL AND U.S. CERVICAL CANCER MARKET, THROUGH 2019 ($ MILLIONS)
TABLE 27 CERVICAL CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
TABLE 28 CERVICAL CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)
CHAPTER 11 OVARIAN CANCER
CAUSE, FREQUENCY AND COURSE
DIAGNOSIS
TREATMENT
PACLITAXEL
CARBOPLATIN
DOXIL
TAXOTERE/DOCETAXEL
CISPLATIN
GEMZAR
HYCAMTIN
NAVELBINE
CARBOPLATIN
OVARIAN CANCER SCREENING
CA125 BLOOD TEST
TRANSVAGINAL ULTRASOUND
NEW DEVELOPMENTS IN TREATMENT
RISK FACTORS AND CAUSES
PREVENTION
DIAGNOSIS
TREATMENT
Chemotherapy
Targeted Therapy
Immunotherapy
ASCO 2013
Asco 2014
Other Developments
TABLE 29 NEW DEVELOPMENTS IN OVARIAN CANCER RESEARCH
MARKET
TABLE 30 GLOBAL AND U.S. OVARIAN CANCER MARKET, THROUGH 2019 ($ MILLIONS)
TABLE 31 OVARIAN CANCER MARKET, FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
TABLE 32 OVARIAN CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)
CHAPTER 12 TUMOR MARKERS
SCREENING AND EARLY DETECTION
DIAGNOSING CANCER
MONITORING
LOOKING FOR RECURRENCE
Tumor Markers Found in Blood or Urine
Alpha-fetoprotein (AFP)
BCR-ABL
Beta-2-microglobulin (B2M)
Beta-HCG
Bladder Tumor Antigen (BTA)
CA 15-3
CA 19-9
CA 27-29
CA 125
Calcitonin
Carcinoembryonic Antigen (CEA)
Chromogranin A
HE-4
Human Chorionic Gonadotropin (HCG)
Immunoglobulins
Free Light Chains
Inhibin
Neuron-specific Enolase (NSE)
NMP22
Prostate-specific Antigen (PSA)
Prostatic Acid Phosphatase (PAP)
S-100
Soluble Mesothelin-Related Peptides (SMRP)
Thyroglobulin
TUMOR MARKERS FOUND ON THE CANCER ITSELF
ANAPLASTIC LYMPHOMA KINASE (ALK)
BRAF
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
HER2 (OR HER2/NEU, ERBB-2, OR EGFR2)
HORMONE RECEPTORS
KRAS
S-100
NEW DIRECTIONS IN TUMOR MARKER RESEARCH
GENOMICS
PROTEOMICS
CHAPTER 13 COMPANY PROFILES
ABBOTT LABORATORIES
ADVAXIS
AMGEN
APP PHARMACEUTICALS
ASTRAZENECA
BAYER
BIONUMERIK PHARMACEUTICALS
BOEHRINGER INGELHEIM GMBH
BRISTOL-MYERS SQUIBB
CELL THERAPEUTICS INC.
CHUGAI PHARMACEUTICAL
CLOVIS ONCOLOGY
DENDREON CORP.
DIGENE CORP.
EISAI INC.
ELI LILLY AND COMPANY
ENDOCYTE
FUJIREBIO DIAGNOSTICS
GE HEALTHCARE
GENENTECH
GLAXOSMITHKLINE
ISA PHARMACEUTICALS
JOHNSON & JOHNSON
LPATH
MERCK
MYRIAD GENETICS
NOVOCURE
OASMIA PHARMACEUTICAL
ONCOLYTICS
OXIGENE
PFIZER
PROVISTA DIAGNOSTICS
QIAGEN
QUEST DIAGNOSTICS
RADIENT PHARMACEUTICALS
ROCHE DIAGNOSTICS
SANOFI
TELIK INC.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
ZILICO
CHAPTER 14 APPENDIX 1: GLOSSARY

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report